Output Explorer

Every prompt in the paper, and what each model wrote back.

Return exactly ten single-sentence facts as JSON. Quality was judged pairwise; here you see the raw outputs and whether the JSON parsed.

13 of 1,000 prompts

MEI · Q4 20252025-07-10 QUIK · Q2 20252025-08-12 AMSF · Q4 20252026-02-26 DNA · Q3 20252025-11-06 NOV · Q1 20262026-04-28 STEM · Q3 20252025-10-29 AVIR · Q4 20252026-03-05 MATV · Q3 20252025-11-06 SATS · Q2 20252025-08-01 BL · Q2 20252025-08-05 CRNX · Q3 20252025-11-06 CLPT · Q2 20252025-08-12 INCY · Q2 20252025-07-29

Nearby prompts. All 1,000 Earnings calls prompts

PromptAVIR· Q4 2025 · call on2026-03-05· transcript 25,975 characters

Analyze the following earnings call transcript and extract the 10 most investor-relevant facts.

Each fact must:
- Be drawn only from the transcript (do not use any outside information).
- Be a single sentence capturing a specific, quantified insight relevant to investors.
- Avoid regurgitating the transcript verbatim; instead, synthesize and distill the information into investor-relevant facts.

Return only a JSON object with this exact structure (no markdown fences, no commentary):
{"facts": ["<fact 1>", "<fact 2>", ..., "<fact 10>"]}

The list must contain exactly 10 facts.

Transcript:
<transcript>
transcript redacted — the source calls are not publicly licensed
</transcript>

System prompt · identical for every setup

You are a financial analyst. You extract the most investor-relevant facts from earnings call transcripts to help investors anticipate the stock's reaction to the call.

Reference

No reference summary is published. Quality was judged pairwise by a separate model and is reported in aggregate on the main page.

Ours

Invalid JSONshown as written

{explore}
{"facts": ["Atea Pharmaceuticals reported holding $301.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025, projecting a cash runway through 2027.", "The company completed enrollment for its North American Phase III trial, C-BEYOND, in December 2025 with over 880 patients, and expects top-line results mid-year 2026.", "Phase II data demonstrated that the eight-week regimen of bemnifosbuvir and ruzasvir achieved a 98% SVR12 cure rate in the per-protocol treatment-adherent population of 275 patients.", "The company selected AT-587 as its lead first-in-class candidate for chronic hepatitis E, a disease with no approved therapy that carries a potential first-year launch in mid-2016.", "Market research with 153 high-prescribing U.S. physicians indicated that approximately 50% of patients would receive the BEM-RZR regimen regardless of cirrhosis status based on Phase II data profiles.", "Atea estimates the unmet market opportunity for immunocompromised patients at $750 million to $1 billion annually, following potential orphan drug designation for the HEV candidate.", "The planned Phase III global program expects to enroll more than 1,760 patients across 240 clinical sites to compare the eight-week Atea regimen against the 12-week standard of care in non-cirrhotic patients.", "Andrea Corcroran confirmed R&D expenses increased in 2025 primarily due to external spending on the HCV Phase III clinical development, offset by lower stock-based compensation and payroll costs.", "The company returned $25 million to stockholders through a share repurchase program in 2025 while maintaining a projected commercial launch sales force of approximately 75 people.", "Preliminary research with U.S. payers indicated a favorable interest in including the BEM-RZR regimen on formularities based on its potential profile of short duration and low drug-drug interaction risk."]}

Aux 2015

Invalid JSONshown as written

Based on the transcript of the Atea Pharmaceuticals, Inc. earnings call, here are the 10 most investor-relevant facts extracted from the transcript:

Hepatitis C Status: The transcript states that the company is conducting the first global Phase III trials in its HCV program, with enrollment in the U.S. and Canada expected midyear and in 17 countries outside North America for C-FORWARD.
HCV Treatment Paradigm Shift: The transcript highlights that the company is advancing its global Phase III program to address the current needs of patients and prescribers, including the test-and-treat model and the need for a new optimized regimen.
HCV Treatment Options: The transcript mentions that the company is conducting the first global Phase III trials in its HCV program, comparing its regimen against the current standard of care (sofosbuvir/velpatasvir) and the standard of care in the U.S. (epclusa).
HCV Treatment Profile: The transcript highlights that the company's regimen has a high barrier to resistance, low risk for drug-drug interactions, and no food effect.
HCV Treatment Duration: The transcript states that the company is conducting the first global Phase III trials in its HCV program, with C-BEYOND enrolling patients in the U.S. and Canada and C-FORWARD enrolling patients in 17 countries outside North America.
HCV Treatment Cost: The transcript mentions that the company is preparing for a commercial launch, with a low cost of goods relative to net price.
HCV Treatment Advantages: The transcript highlights that the company's regimen has a high efficacy, short treatment duration, low risk for drug-drug interactions, and convenience with no food effect.
HCV Treatment Advantages (continued): The transcript mentions that the company is advancing its global Phase III program to address the current needs of patients and prescribers, including the test-and-treat model and the need for a new optimized regimen.
HCV Treatment Advantages (continued): The transcript highlights that the company's regimen has a high barrier to resistance, low risk for drug-drug interactions, and no food effect.
HCV Treatment Advantages (continued): The transcript mentions that the company is advancing its global Phase III program to address the current needs of patients and prescribers, including the test-and-treat model and the need for a new optimized regimen.

These facts are drawn from the transcript and are directly relevant to investors in the context of the company's HCV program.

PiT-FT 2015

Invalid JSONshown as written

<|assistant|>
<|assistant|>
<|assistant|>

The same 14-character fragment repeats 292 times until the token limit. Showing the first three.

ChronoGPT 2015

Invalid JSONshown as written


### Final Answer: